AP NEWS
Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18), 18F-Fluciclovine and 18F-rhPSMA at Upcoming ASTRO Annual Meeting

September 10, 2019

BURLINGTON, Mass. & OXFORD, England--(BUSINESS WIRE)--Sep 10, 2019--

Blue Earth Diagnostics, a Bracco company focused on molecular imaging diagnostics, today announced upcoming presentations at the 2019 American Society for Radiation Oncology (ASTRO) Annual Meeting, from September 15 – 18, 2019 in Chicago, Ill.

Highlighted presentations encompass the clinical use of Axumin ® (fluciclovine F 18) injection, including full results of the FALCON clinical study, which investigated the impact of 18 F-fluciclovine PET on the management of patients with recurrent prostate cancer. The initial clinical experience by the Technical University of Munich with 18 F-rhPSMA-7, an investigational Prostate Specific Membrane Antigen-targeted radiohybrid PET imaging agent representative of the family of rhPSMA agents that Blue Earth Diagnostics exclusively licensed in 2018, will also be presented. Details of selected oral and poster presentations by Blue Earth Diagnostics and its collaborators are listed below.

NOTE: Axumin ® (fluciclovine F 18) injection is FDA-approved for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. Presentations noted by “*” discuss results of investigational studies of an approved product that is not approved by the FDA for the specific use or purpose noted, or “*” denotes experience with an investigational agent for which the safety and efficacy have not been established by the FDA.

HIGHLIGHTED SCIENTIFIC PRESENTATIONS

Blue Earth Diagnostics invites participants at the 2019 ASTRO Annual Meeting to attend the presentations above and to visit the company at Exhibit Booth 1439. The company is also hosting an Industry-Expert Theater event, “Detecting and Localizing Recurrent Prostate Cancer with Axumin ® (Fluciclovine F 18) Injection,” with invited speaker Dr. Jonathan D. Tward, MD, PhD, Huntsman Cancer Institute, University of Utah, which will be held on Sunday, September 15, 2019, from 12:15 – 1:15 p.m. CT, in Theater 1, Innovation Hub.

U.S. Indication and Important Safety Information About Axumin

INDICATION

Axumin ® (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.

IMPORTANT SAFETY INFORMATION

To report suspected adverse reactions to Axumin, call 1-855-AXUMIN1 (1-855-298-6461) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Full Axumin prescribing information is available at www.axumin.com.

About Axumin ® (fluciclovine F 18)

Axumin ® (fluciclovine F 18) injection is a novel product indicated for use in positron emission tomography (PET) imaging to identify suspected sites of prostate cancer recurrence in men. Recurrence of prostate cancer is suspected by an increase in prostate specific antigen (PSA) levels following prior treatment. PET imaging with Axumin may identify the location and extent of such recurrence. Axumin was developed to enable visualization of the increased amino acid transport that occurs in many cancers, including prostate cancer. It consists of a synthetic amino acid that is preferentially taken up by prostate cancer cells compared with surrounding normal tissues and is labeled with the radioisotope F 18 for PET imaging. Fluciclovine F 18 was invented at Emory University in Atlanta, Ga., with much of the fundamental clinical development work carried out by physicians at Emory University’s Department of Radiology and Imaging Sciences. Axumin was approved by the U.S. Food and Drug Administration in May 2016, following Priority Review, and is the first product commercialized by Blue Earth Diagnostics, which licensed the product from GE Healthcare. The molecule is being investigated by Blue Earth Diagnostics for other potential cancer indications including in neuro-oncology.

About rhPSMA

Blue Earth Diagnostics acquired exclusive, worldwide rights to radiohybrid Prostate Specific Membrane Antigen (PSMA)-targeted technology (rhPSMA) from Scintomics in 2018. rhPSMA originated from the Chair of Pharmaceutic Radiochemistry at the Technical University of Munich, Germany, by Alexander Wurzer and Hans Juergen Wester, and has been utilized clinically under German legislation at the Department of Nuclear Medicine for the diagnostic imaging of men with both primary and recurrent prostate cancer. 18 F-rhPSMA consists of a prostate-specific membrane antigen (PSMA) receptor ligand, which attaches to and is internalized by prostate cancer cells, and is labeled with the 18 F radioisotope for PET imaging. rhPSMA compounds can also be labeled with radioisotopes such as 177 Lu and 225 Ac for therapeutic use. 18 F-rhPSMA, 177 Lu-rhPSMA and 225 Ac-rhPSMA have not received regulatory approval.

About Blue Earth Diagnostics

Blue Earth Diagnostics is a leading molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Formed in 2014, Blue Earth Diagnostics is led by recognized experts in the clinical development and commercialization of innovative nuclear medicine products. The company’s first approved and commercially available product is Axumin ® (fluciclovine F 18), a novel molecular imaging agent approved in the United States and European Union for use in PET imaging to detect and localize prostate cancer in men with a diagnosis of biochemical recurrence. Fluciclovine F 18 has a broad range of other potential applications in cancer imaging and Blue Earth Diagnostics is investigating the molecule for other cancers including in neuro-oncology. The company’s pipeline includes innovative Prostate Specific Membrane Antigen (PSMA)-targeted radiohybrid (“rh”) agents, which are a clinical-stage, investigational class of theranostic compounds, with potential applications in both the imaging and treatment of prostate cancer. Blue Earth Diagnostics is a subsidiary of Bracco Imaging S.p.A., a global leader in diagnostic imaging. For more information, visit: www.blueearthdiagnostics.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190910005204/en/

CONTACT: For Blue Earth Diagnostics (U.S.)

Priscilla Harlan

Vice President, Corporate Communications

(M) (781) 799-7917

p.harlan@blueearthdx.comMedia

Sam Brown Inc.

Mike Beyer

(M) (312) 961-2502

mikebeyer@sambrown.comFor Blue Earth Diagnostics (UK)

Georgina Mowatt

Communications Manager

Tel: +44 (0) 7810 355 912

g.mowatt@blueearthdx.com

KEYWORD: NORTH AMERICA UNITED STATES UNITED KINGDOM EUROPE ILLINOIS MASSACHUSETTS

INDUSTRY KEYWORD: BIOTECHNOLOGY MEN HEALTH CONSUMER RADIOLOGY PHARMACEUTICAL ONCOLOGY RESEARCH HOSPITALS SCIENCE

SOURCE: Blue Earth Diagnostics

Copyright Business Wire 2019.

PUB: 09/10/2019 08:30 AM/DISC: 09/10/2019 08:31 AM

http://www.businesswire.com/news/home/20190910005204/en

All contents © copyright 2019 The Associated Press. All rights reserved.